Paolo Di Giorgio is the Chief Executive Officer and Managing Director of Angelini Ventures, the corporate venture arm of Angelini Industries. The fund’s recent investments include a participation in Argobio, a european start-up studio, the co-founding of the Angelini Lumira Bioscience Fund, a fund that invests in early stage CNS companies in north America, and an investment in Pretzel Therapeutics, a company developing innovative therapeutics for mitochondrial disorders.

Paolo is a life sciences executive with over 15 years of experience in venture capital, R&D, external innovation and business development at Merck, Novartis and Angelini Pharma. Originally a neuroscientist by training, he has led global teams on several projects in different therapeutic areas such as neuroscience, pain, rare diseases, anti-infectives, oncology, and metabolic disorders.

During his Ph.D and post-doctoral studies at Harvard University and at the Salk Institute for Biological Studies, Paolo pioneered a novel method to study neurodegenerative diseases using stem cell-derived neurons. Paolo has also completed an executive MBA program at IE Business School in Madrid, Spain.